Pregnancy and Multiple Sclerosis

Maria K. Houtchens

doi:10.1055/s-2007-991127

Seminars in Neurology, Table of Contents

Semin Neurol 2007; 27(5): 434-441
DOI: 10.1055/s-2007-991127

Pregnancy and Multiple Sclerosis

Maria K. Houtchens¹

¹Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Brookline, Massachusetts

Abstract

ABSTRACT

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system affecting predominantly women of childbearing age; therefore, issues of conception, pregnancy, and delivery become of significant importance to patients and treating physicians. This article discusses the immunological and clinical effects of pregnancy on the course of MS, clinical outcomes of Pregnancy in Multiple Sclerosis (PRIMS) trials, the available data on safety and efficacy of immunomodulating MS treatments and symptomatic treatments for pregnant and lactating women, and specific issues of MS management at the time of pregnancy. The data related to estrogen-based MS therapies currently or previously in trials are reviewed. Pregnancy does not appear to be associated with adverse outcomes in MS patients. Some evidence suggests possible beneficial effects, although clear prospective data of sufficient length are limited. Long-term relapse rates and disability progression do not seem to be affected by pregnancy in MS patients. The use of immunosuppressive or immunomodulatory agents in pregnancy is not routinely advisable.

KEYWORDS

Multiple sclerosis - pregnancy

Full Text

References

REFERENCES

1 Douglass L H, Jorgensen C L. Pregnancy and multiple sclerosis. Am J Obstet Gynecol. 1948; 55 332-336
2 Confavreux C, Hutchinson M, Hours M, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998; 339 285-291
3 Vukusic S, Hutchinson M, Hours M et al.. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004; 127 1353-1360
4 Rossouw J E, Anderson G L, Prentice R L et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 288 321-333
5 Thorogood M, Hannaford P C. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol. 1998; 105 1296-1299
6 Alonso A, Jick S S, Olek M J, Ascherio A, Jick H, Hernán M A. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol. 2005; 62 1362-1365
7 Dwosh E, Guimond C, Sadovnick A D. Reproductive counselling for MS: a rationale. Int MS J. 2003; 10 52-59
8 Zorzon M, Zivadinov R, Bosco A et al.. Sexual dysfunction in multiple sclerosis: a case-control study. Frequency and comparison of groups. Mult Scler. 1999; 5 418-427
9 Hughes M D. Multiple sclerosis and pregnancy. Neurol Clin. 2004; 22 757-769
10 Sadovnick A D, Baird P A, Ward R H. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 1988; 29 533-541
11 Hunt J S. Immunobiology of pregnancy. Curr Opin Immunol. 1992; 4 591-596
12 Damek D M, Shuster E A. Pregnancy and multiple sclerosis. Mayo Clin Proc. 1997; 72 977-989
13 Athanasas-Platsis S, Zhang B, Hillyard N C et al.. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis. J Neurol Sci. 2003; 214 27-36
14 Drew P D, Chavis J A. Female sex steroids: effects upon microglial cell activation. J Neuroimmunol. 2000; 111 77-85
15 Gilmore W, Arias M, Stroud N, Stek A, McCarthy K A, Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients. J Neurol Sci. 2004; 224 69-76
16 Abramsky O, Brenner T, Mirzachi R, Soffer D. Alpha-fetoprotein suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 1982; 2 1-7
17 Altman D J, Schneider S L, Thompson D A, Cheng H L, Tomasi T B. A transforming growth factor beta 2 (TGF-beta-2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus. J Exp Med. 1990; 172 1391-1401
18 Correale J, Gilmore W, McMillan M et al.. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T lymphocytes. J Immunol. 1995; 154 2959-2968
19 Byrnes A A, McArthur J C, Karp C L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin 10 production. Ann Neurol. 2002; 51 165-174
20 López C, Comabellaa M, Tintoré M, Sastre-Garriga J. X Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. Mult Scler. 2006; 12 421-427
21 Saraste M, Ryynänen J, Alanen J et al.. Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy. J Neurol Neurosurg Psychiatry. 2006; 77 1195-1196
22 Weinshenker B G, Bass B, Rice G P et al.. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112 133-146
23 Frith J A, Mcleod J G. Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988; 51 495-498
24 Birk K, Ford C, Smeltzer S et al.. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol. 1990; 47 738-742
25 Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: The children of PRIMS. Clin Neurol Neurosurg. 2006; 108 266-270
26 Kurtzke J F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33 1444-1452
27 Salemi G, Callari G, Gammino M et al.. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand. 2004; 110 23-26
28 Runmarker B, Anderson O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995; 118 253-261
29 Stenager E, Stenager E N, Jensen K. Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation. Acta Neurol Scand. 1994; 90 305-308
30 Mueller B A, Zhang J, Critchlow C W. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol. 2002; 186 446-452
31 Worthington J, Jones R, Crawford M et al.. Pregnancy and multiple sclerosis: a 3-year prospective study. J Neurol. 1994; 241 228-233
32 Dahl J, Myhr K M, Daltveit A K, Hoff J M, Gilhus N E. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005; 65 1961-1963
33 de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. 2004; 10 596-597
34 Janssen N M, Genta S G. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch Intern Med. 2000; 160 610-619
35 Penn I, Makowski E, Droegemueller W, Halgrimson C G, Starzl T E. Parenthood in renal transplant recipients. JAMA. 1971; 216 1755-1761
36 Kozlowski R D, Steinbrunner J V, McKenzie A H, Clough J D, Wilke W S, Segal A M. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990; 88 589-592
37 Nguyen C, Duhl A J, Excallon C S, Blakemore K J. Multiple anomalies in a fetus exposed to a low-dose methotrexate in the first trimester of pregnancy. Obstet Gynecol. 2002; 99 599-602
38 Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001; 71 1051-1055
39 Walther E U, Hohlfeld R. Multiple sclerosis: side-effects of interferon beta therapy and their management. Neurology. 1999; 53 1622-1627
40 Coyle P K, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate. In: Proceedings of the 55th Annual Meeting of the American Academy of Neurology. Neurology. 2003; 60(suppl 1) A60
41 Boskovic R, Wide R, Wolpin J, Bauer D J, Koren G. The reproductive effects of beta interferon therapy in pregnancy. a longitudinal cohort. Neurology. 2005; 65 807-811
42 Waubant E, Sadovnick A D. Interferon beta babies. Neurology. 2005; 65 788-789
43 Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of child-birth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol. 1996; 243 25-28
44 Van Walderveen M AA, Tas M W, Barkhof F. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology. 1994; 44 327-329
45 Voskuhl R R, Palaszynski K. Sex hormones and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist. 2001; 7 258-270
46 Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol. 1994; 53 203-207
47 Sicotte N L, Liva S M, Klutch R et al.. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002; 52 421-428
48 Rizvi S A, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology. 2004; 63(suppl 6) S47-S54

Maria K HoutchensM.D. M.Sc.

Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School

1 Brookline Place, #225, Brookline, MA 02445

Email: mhoutchens@partners.org